	US 12,344,670 B2
	Anti-ILT4 antibodies and antigen-binding fragments
Milan Blanusa, Jena (DE); Barbara Joyce-Shaikh, San Jose, CA (US); Andrea Claudia Schuster, Jena (DE); Kornelia Schultze, Jena (DE); and Luis A. Zuniga, Mountain View, CA (US)
Assigned to Agenus Inc., Lexington, MA (US); and Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US); and Agenus Inc., Lexington, MA (US)
Filed on Dec. 20, 2023, as Appl. No. 18/389,914.
Application 17/338,566 is a division of application No. 15/945,779, filed on Apr. 5, 2018, granted, now 11,053,315, issued on Jul. 6, 2021.
Application 18/389,914 is a continuation of application No. 17/338,566, filed on Jun. 3, 2021, granted, now 11,897,956.
Claims priority of provisional application 62/483,019, filed on Apr. 7, 2017.
Prior Publication US 2024/0228614 A1, Jul. 11, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

10 Claims

1. A method for detecting an ILT4 peptide or fragment thereof in a sample, comprising contacting the sample with an antibody or antigen-binding fragment thereof that binds human ILT4, wherein the antibody or antigen-binding fragment thereof comprises:

(1) a heavy chain variable domain comprising:

CDR-H1: GYYWS (SEQ ID NO: 16),

CDR-H2: EINHXGSTNYNPSLKS wherein X is S or A (SEQ ID NO: 17), and

CDR-H3: LPTRWVTTRYFDL (SEQ ID NO: 18); and,

a light chain variable domain comprising:

CDR-L1: TGSSSNIGAGYDVH (SEQ ID NO: 19),

CDR-L2: GX1X2NRPS, wherein X1 is N, Q, E or D and X2 is S or A (SEQ ID NO: 20), and

CDR-L3: QSFDNSLSAYV (SEQ ID NO: 21);

(2) a heavy chain variable domain comprising:

CDR-H1: SYAIS (SEQ ID NO: 22),

CDR-H2: GIIPIFGTANYAQKFOG (SEQ ID NO: 23), and

CDR-H3: YFX1X2SGWYKGGAFDI, wherein X1 is D or S and X2 is S or A (SEQ ID NO: 24); and,

a light chain variable domain comprising:

CDR-L1: TLRSGINVDTYRIH (SEQ ID NO: 25),

CDR-L2: YKSDSDKHOGS (SEQ ID NO: 26), and

CDR-L3: AIWYSSTWV (SEQ ID NO: 27);

(3) a heavy chain variable domain comprising:

CDR-H1: SYAMH (SEQ ID NO: 28),

CDR-H2: VISYDGSNKYYADSVKG (SEQ ID NO: 29), and

CDR-H3: VGEWIQLWSPFDY (SEQ ID NO: 30); and,

a light chain variable domain comprising:

CDR-L1: RASQGISSWLA (SEQ ID NO: 31),

CDR-L2: AASSLOS (SEQ ID NO: 32), and

CDR-L3: QQYNSYPPT (SEQ ID NO: 33); or

(4) a heavy chain variable domain comprising:

CDR-H1: ELSMH (SEQ ID NO: 34),

CDR-H2: GFDPEDGETIYAQKFOG (SEQ ID NO: 35), and

CDR-H3: AGPLYTIFGVVIIPDNWFDP (SEQ ID NO: 36); and,

a light chain variable domain comprising:

CDR-L1: TGSSSNIGAGYDVH (SEQ ID NO: 37),

CDR-L2: GNSNRPS (SEQ ID NO: 38), and

CDR-L3: QSYDSSLSGSGVV (SEQ ID NO: 39), and detecting the presence of a complex between the antibody or antigen-binding fragment thereof and the ILT4 peptide or fragment thereof; wherein detection of the complex indicates the presence of the ILT4 peptide or fragment thereof.